What Is Type 1 Diabetes? Causes, Symptoms, and Management

What Is Type 1 Diabetes?

Type 1 diabetes (T1D) is a chronic autoimmune disease in which the body's immune system mistakenly destroys the insulin-producing beta cells in the pancreas. Without these cells, the body cannot produce insulin — the hormone necessary to allow glucose (sugar) to enter cells and be used for energy. Without insulin, blood sugar levels rise dangerously high, while cells starve for fuel.

Type 1 diabetes affects approximately 1.6 million Americans and 8–9 million people worldwide. Unlike type 2 diabetes, which is primarily driven by insulin resistance, type 1 is an absolute insulin deficiency — people with T1D require insulin therapy to survive.

Causes: Autoimmune Destruction

In T1D, the immune system produces autoantibodies that target beta cells in the islets of Langerhans in the pancreas. The exact trigger for this autoimmune attack is not fully understood, but it involves a combination of:

• Genetic predisposition: Certain HLA (human leukocyte antigen) gene variants dramatically increase risk. Having a first-degree relative with T1D increases risk 10-fold, but only ~10% of people with T1D have an affected relative — genetics is necessary but not sufficient.
• Environmental triggers: Viral infections (particularly enteroviruses like Coxsackievirus), early diet, gut microbiome composition, and environmental exposures may trigger the autoimmune response in genetically susceptible individuals

By the time symptoms appear, 80–90% of beta cells have already been destroyed. The disease process often begins months to years before diagnosis.

Type 1 vs. Type 2 Diabetes

• Mechanism: T1D = autoimmune destruction (can't produce insulin); T2D = insulin resistance (body doesn't use insulin effectively)
• Insulin: T1D always requires insulin. T2D often managed with diet, exercise, oral medications, with insulin added later if needed.
• Onset: T1D classically appears in childhood/adolescence (hence former name "juvenile diabetes") but occurs at any age. T2D primarily in adults over 45, though increasingly in younger people.
• Prevention: T2D can often be prevented or delayed with lifestyle changes. T1D cannot currently be prevented.
• Weight: T1D unrelated to weight. T2D strongly associated with obesity.

Symptoms and Diagnosis

Classic symptoms (the "4 T's" recognized in the UK):

• Thirst: Excessive thirst (polydipsia)
• Toilet: Frequent urination (polyuria)
• Tired: Extreme fatigue
• Thinner: Unexplained weight loss

Additional symptoms: blurred vision, fruity breath odor, nausea. Untreated T1D leads to diabetic ketoacidosis (DKA) — a life-threatening condition where the body breaks down fat for energy, producing acidic ketones.

Diagnosis involves blood glucose tests (random glucose ≥ 200 mg/dL with symptoms, or fasting glucose ≥ 126 mg/dL), HbA1c (measures average blood sugar over 3 months), and presence of autoantibodies (anti-GAD65, anti-IA-2, anti-ZnT8).

Insulin Therapy

People with T1D must replace insulin artificially. Modern insulin therapy involves:

• Basal insulin: Long-acting insulin (glargine, detemir, degludec) that provides a steady background level throughout the day
• Bolus insulin: Rapid-acting insulin (lispro, aspart, glulisine) taken at meals, timed to match carbohydrate intake
• Multiple daily injections (MDI): Typically 4–6 shots per day
• Insulin pump (CSII): A small wearable device that delivers continuous basal and bolus doses via a subcutaneous catheter, eliminating most injections

Monitoring Blood Sugar

• Continuous glucose monitors (CGM): A small sensor worn on the skin (Dexterity G7, Libre) that measures glucose every 1–5 minutes and transmits data to a phone or pump. Has transformed diabetes management.
• Finger-stick blood glucose meters: Traditional method, still used for calibration

The Artificial Pancreas (Closed-Loop Systems)

The most significant recent advance: closed-loop insulin delivery (sometimes called artificial pancreas) combines a CGM with an insulin pump controlled by an algorithm that automatically adjusts insulin delivery based on real-time glucose readings.

The FDA-approved Control-IQ (Tandem) and Omnipod 5 systems have dramatically improved time-in-range (the percentage of time glucose stays between 70–180 mg/dL) for people with T1D, reducing both dangerous lows and highs with minimal user intervention. These systems represent the closest thing to an artificial pancreas available today.